SGMT
NASD Sagimet Biosciences Inc. Class A$9.02 ↑ +0.10 (+1.10%) Trading Up from the previous close of $8.92
- YTD change
- +52.33%
- vs 20-day SMA
- -9.30%
- vs 200-day SMA
- +24.75%
Price ranges
Price & Performance
+3.28 (+58.16%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 56.5% away from all-time highs of $20.71
- SGMT is up 52% since the beginning of the year
- SGMT is up 5% over the past 12 months
- SGMT is down 18% over the past 1 month
- 16% of all SGMT investors are betting against SGMT
SGMT reads neutral: price sits above one of the two key moving averages, the 12-month move is +3.5%.
- Previous minute
- -$0.46
- Last hour
- +$0.27
- Last 5 days
- -3.76%
- vs 8-day SMA
- -1.59%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
